Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04978428
PHASE2

Epidiolex in Obsessive Compulsive Disorder and Related Disorders

Sponsor: University of Chicago

View on ClinicalTrials.gov

Summary

The primary objective of the proposed study is to evaluate the safety and efficacy of Epidiolex (cannabidiol) in adults with obsessive compulsive and related disorders (OCRDs). Subjects will be treated in an open-label fashion with Epidiolex for two weeks.

Official title: An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder and Related Disorders: Proof of Concept Study

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

4

Start Date

2022-04-14

Completion Date

2025-11-01

Last Updated

2026-07-29

Healthy Volunteers

No

Interventions

DRUG

Cannabidiol

Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)

Locations (1)

University of Chicago

Chicago, Illinois, United States